Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Metabolomic Signature of Early Vascular Aging (EVA) in Hypertension

Polonis, Katarzyna ; Wawrzyniak, Renata ; Daghir-Wojtkowiak, Emilia ; Szyndler, Anna ; Chrostowska, Marzena ; Melander, Olle LU orcid ; Hoffmann, Michał ; Kordalewska, Marta ; Raczak-Gutknecht, Joanna and Bartosińska, Ewa , et al. (2020) In Frontiers in Molecular Biosciences 7.
Abstract

Arterial stiffening is a hallmark of early vascular aging (EVA) syndrome and an independent predictor of cardiovascular morbidity and mortality. In this case-control study we sought to identify plasma metabolites associated with EVA syndrome in the setting of hypertension. An untargeted metabolomic approach was used to identify plasma metabolites in an age-, BMI-, and sex-matched groups of EVA (n = 79) and non-EVA (n = 73) individuals with hypertension. After raw data processing and filtration, 497 putative compounds were characterized, out of which 4 were identified as lysophosphaditylcholines (LPCs) [LPC (18:2), LPC (16:0), LPC (18:0), and LPC (18:1)]. A main finding of this study shows that identified LPCs were independently... (More)

Arterial stiffening is a hallmark of early vascular aging (EVA) syndrome and an independent predictor of cardiovascular morbidity and mortality. In this case-control study we sought to identify plasma metabolites associated with EVA syndrome in the setting of hypertension. An untargeted metabolomic approach was used to identify plasma metabolites in an age-, BMI-, and sex-matched groups of EVA (n = 79) and non-EVA (n = 73) individuals with hypertension. After raw data processing and filtration, 497 putative compounds were characterized, out of which 4 were identified as lysophosphaditylcholines (LPCs) [LPC (18:2), LPC (16:0), LPC (18:0), and LPC (18:1)]. A main finding of this study shows that identified LPCs were independently associated with EVA status. Although LPCs have been shown previously to be positively associated with inflammation and atherosclerosis, we observed that hypertensive individuals characterized by 4 down-regulated LPCs had 3.8 times higher risk of EVA compared to those with higher LPC levels (OR = 3.8, 95% CI 1.7–8.5, P < 0.001). Our results provide new insights into a metabolomic phenotype of vascular aging and warrants further investigation of negative association of LPCs with EVA status. This study suggests that LPCs are potential candidates to be considered for further evaluation and validation as predictors of EVA in patients with hypertension.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
arterial stiffness, early vascular aging, metabolomics, phospholipid metabolism, pulse wave velocity
in
Frontiers in Molecular Biosciences
volume
7
article number
12
publisher
Frontiers Media S. A.
external identifiers
  • scopus:85079783361
  • pmid:32118038
ISSN
2296-889X
DOI
10.3389/fmolb.2020.00012
language
English
LU publication?
yes
id
a75ddee2-359d-4a2b-964b-1a357dcc2c78
date added to LUP
2020-03-12 08:54:35
date last changed
2024-04-17 05:10:33
@article{a75ddee2-359d-4a2b-964b-1a357dcc2c78,
  abstract     = {{<p>Arterial stiffening is a hallmark of early vascular aging (EVA) syndrome and an independent predictor of cardiovascular morbidity and mortality. In this case-control study we sought to identify plasma metabolites associated with EVA syndrome in the setting of hypertension. An untargeted metabolomic approach was used to identify plasma metabolites in an age-, BMI-, and sex-matched groups of EVA (n = 79) and non-EVA (n = 73) individuals with hypertension. After raw data processing and filtration, 497 putative compounds were characterized, out of which 4 were identified as lysophosphaditylcholines (LPCs) [LPC (18:2), LPC (16:0), LPC (18:0), and LPC (18:1)]. A main finding of this study shows that identified LPCs were independently associated with EVA status. Although LPCs have been shown previously to be positively associated with inflammation and atherosclerosis, we observed that hypertensive individuals characterized by 4 down-regulated LPCs had 3.8 times higher risk of EVA compared to those with higher LPC levels (OR = 3.8, 95% CI 1.7–8.5, P &lt; 0.001). Our results provide new insights into a metabolomic phenotype of vascular aging and warrants further investigation of negative association of LPCs with EVA status. This study suggests that LPCs are potential candidates to be considered for further evaluation and validation as predictors of EVA in patients with hypertension.</p>}},
  author       = {{Polonis, Katarzyna and Wawrzyniak, Renata and Daghir-Wojtkowiak, Emilia and Szyndler, Anna and Chrostowska, Marzena and Melander, Olle and Hoffmann, Michał and Kordalewska, Marta and Raczak-Gutknecht, Joanna and Bartosińska, Ewa and Kaliszan, Roman and Narkiewicz, Krzysztof and Markuszewski, Michał J.}},
  issn         = {{2296-889X}},
  keywords     = {{arterial stiffness; early vascular aging; metabolomics; phospholipid metabolism; pulse wave velocity}},
  language     = {{eng}},
  month        = {{02}},
  publisher    = {{Frontiers Media S. A.}},
  series       = {{Frontiers in Molecular Biosciences}},
  title        = {{Metabolomic Signature of Early Vascular Aging (EVA) in Hypertension}},
  url          = {{http://dx.doi.org/10.3389/fmolb.2020.00012}},
  doi          = {{10.3389/fmolb.2020.00012}},
  volume       = {{7}},
  year         = {{2020}},
}